S108 Evaluation of optimale usage of intravesical instilation of bacillus Calmette-Guérin after transurethral resection of non – muscle invasive bladder tumour

2013 ◽  
Vol 12 (4) ◽  
pp. e1216, S108
Author(s):  
R. Milosevic ◽  
N. Milovic ◽  
P. Aleksic ◽  
M. Lazic ◽  
S. Cerovic ◽  
...  
Keyword(s):  
Transurethral Resection ◽  
Bladder Tumour ◽  
Bacillus Calmette Guerin ◽  
Muscle Invasive

scholarly journals A prospective observational study to evaluate the role of restaging transurethral resection of bladder tumour in patients with non-muscle invasive bladder cancer

2019 ◽  
Vol 7 (11) ◽  
pp. 4134
Author(s):  
Kishan K. Raj ◽  
Yogesh Taneja ◽  
Prateek Ramdev ◽  
Santosh K. Dhaked ◽  
Charan K. Singh ◽  
...  
Keyword(s):  
Risk Factors ◽  
Transurethral Resection ◽  
Prospective Observational Study ◽  
Residual Disease ◽  
Bladder Tumour ◽  
Detrusor Muscle ◽  
Residual Tumour ◽  
Muscle Invasive Bladder Cancer ◽  
T1 Stage ◽  
Muscle Invasive

Background: Transurethral resection of bladder tumour (TURBT) is the primary treatment modality for Non-muscle invasive bladder cancer (NMIBC). Restaging transurethral resection of bladder tumour (RETURBT) is indicated to reduce risk of residual disease and correct staging errors after primary TURBT. The aim of the study is to evaluate the risk of residual tumour and upstaging in NMIBC after TURBT and to investigate the risk factors for the same.Methods: A prospective observational study was carried out over 4 years and 87 patients were included in the study. Patients with NMIBC underwent RETURBT after 2-6 weeks of primary TURBT. The incidence of residual tumour and upstaging in RETUBRT was correlated with various histopathological and morphological parameters in primary TURBT.Results: Out of 87 patients, who underwent RETURBT, residual disease was present in 51 patients (58.6%) and upstaging occurred in 22 patients (25.2%).On univariate analysis, T1 stage (p=0.01), high grade (p=0.01), Carcinoma in situ(CIS) (p=0.01) and multifocality (p=0.05) were predictive for residual disease in RETURBT. High grade (p=0.01), CIS (p=0.01) and absence of detrusor muscle in specimen (p=0.03) were risk factors for upstaging in RETURBT.Conclusions: NMIBC have high incidence of residual disease and upstaging after primary TURBT. T1 stage, high tumour grade, CIS, and multifocality are risk factors for residual disease after primary TURBT. High tumour grade, CIS and absence of detrusor muscle are strongly associated with upstaging during RETURBT.

Routine preoperative group and save for TURP and TURBT – need and cost effectiveness

2017 ◽  
Vol 11 (1) ◽  
pp. 33-37
Author(s):  
Hazel Smith ◽  
Rachel Falconer ◽  
Justyna Szczachor ◽  
Sarfraz Ahmad
Keyword(s):  
Risk Factors ◽  
Cost Effectiveness ◽  
Blood Transfusion ◽  
Transurethral Resection ◽  
Bladder Tumour ◽  
Transurethral Resection Of Prostate ◽  
Junior Doctors ◽  
Two Samples ◽  
Muscle Invasive ◽  
One Year

Introduction: Standard practice in our unit is to take a group and save (G+S) blood sample for all patients undergoing a transurethral resection of prostate (TURP) and transurethral resection of bladder tumour (TURBT). Modern studies show the transfusion rates for TURP are 2%–7% and for TURBT 2%. Aims: We will determine how many patients undergoing TURP and TURBT required blood transfusion, analyse the indication, timing and risk factors. Additionally we will assess the cost effectiveness of routine G+S. Methods: A retrospective analysis was conducted between 1 March 2015 and 29 February 2016 (one year). Patients were identified from OPERA database and cross-referenced with blood transfusion records. Electronic case notes for patients receiving transfusions were reviewed. Results: A total of 167 patients underwent TURP. Of these, 0.6% (1/167) received transfusion on day 4 post-op. A total of 160 patients underwent TURBT. Overall 3.8% (6/160) received transfusion: three patients on days 0–1 and three patients on days 2–30. All patients had pre-op Hb <100 g/l. All had large muscle-invasive tumours. Cost in our lab of a G+S sample is £23.52. Two samples are now required before blood can be issued. Discussion: Our study shows that risk factors for transfusion are large prostates, likely muscle-invasive bladder tumours and pre-op Hb <100 g/l. Other risks include coagulopathy. These will usually be identified by the surgeon or pre-assessment clinic prior to the procedure. Change in policy would save money and time of phlebotomists and junior doctors. Conclusions: Routine G+S is not necessary for all patients. Patients with risk factors can be identified preoperatively. This would give a potential saving of over £15,000 per year. This can be implemented without adversely affecting patient safety.

Sign in / Sign up

Export Citation Format

Share Document